About Meiogenix
Meiogenix is a company based in Paris (France) founded in 2010. Meiogenix has raised $13 million across 3 funding rounds from investors including ARE, Bpifrance and Kurma Partners. Meiogenix offers products and services including Chromosome Editing. Meiogenix operates in a competitive market with competitors including GSK, Benson Hill, Avidity Biosciences, Sutro Biopharma and Antheia, among others.
- Headquarter Paris, France
-
Sectors
HealthcareAgriculture
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Meiogenix Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$13 M (USD)
in 3 rounds
-
Latest Funding Round
$13 M (USD), Series A
Dec 14, 2021
-
Investors
ARE
& 5 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Meiogenix
Meiogenix offers a comprehensive portfolio of products and services, including Chromosome Editing.
Edits crop chromosomes to unlock genetic diversity for addressing farming challenges.
People of Meiogenix
Unlock access to complete
Unlock access to complete
Funding Insights of Meiogenix
Meiogenix has successfully raised a total of $13M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $13 million completed in December 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Meiogenix
Meiogenix has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, Bpifrance and Kurma Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Sofinnova Partners is focused on life sciences and healthcare investments.
|
Locked | Locked | Locked | |
|
Early-stage VC firm focused on life science startups
|
Locked | Locked | Locked | |
|
Investing in Life Sciences sectors like Healthcare and Biotechnology.
|
Locked | Locked | Locked |
Investor details for Meiogenix
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Meiogenix
Investment portfolio details for Meiogenix
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Meiogenix
Detailed financials for Meiogenix
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Meiogenix Comparisons
Peer comparison for Meiogenix
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Meiogenix
Meiogenix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Benson Hill, Avidity Biosciences, Sutro Biopharma and Antheia, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| Locked | Locked | Locked |
Provider of plant-based food ingredients
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
Detailed competitors of Meiogenix
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Meiogenix
Complete news archive for Meiogenix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Meiogenix
Meiogenix was founded in 2010.
Meiogenix is headquartered in Paris, France.
Luc Mathis is the current CEO of Meiogenix.
Meiogenix is a funded company, having raised a total of $13M across 3 funding rounds to date.
Meiogenix was founded in 2010 and is based in Paris, France. Operations focus on the agricultural biotechnology sector, where novel breeding technologies for crop plants are developed. A fusion protein platform is utilized to enhance recombination rates in cold regions. Solutions aimed at improving crop resilience, quality, and yield are pursued through these technologies.
Meiogenix's top competitors include Benson Hill, Sutro Biopharma and Cibus.
Meiogenix offers Chromosome Editing.
Meiogenix has 6 investors. Key investors include ARE, Bpifrance, Kurma Partners, Sofinnova Partners, and Genoa Ventures.